IPO Year: 2025
Exchange: AMEX
| Date | Price Target | Rating | Analyst |
|---|
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
4 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Issuer)
PREM14C - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K/A - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
425 - Apimeds Pharmaceuticals US, Inc. (0001894525) (Subject)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
8-K - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
10-Q - Apimeds Pharmaceuticals US, Inc. (0001894525) (Filer)
Fastest customizable press release news feed in the world
NEW YORK, Dec. 17, 2025 (GLOBE NEWSWIRE) -- E.F. Hutton is proud to have served as an Exclusive M&A Advisor in the recently completed merger between Apimeds Pharmaceuticals US Inc. (NYSE:APUS) and Mindwave Innovations Inc. The merger brings together a biotech development platform with an AI-powered digital treasury infrastructure supported by a $100 million PIPE commitment, for which E.F. Hutton acted as Placement Agent. E.F. Hutton's involvement underscores its commitment to advancing the combined company's strategic growth across late-stage biotech development and institutional Digital Asset Treasury Solutions. E.F. Hutton worked closely with both companies to shape the transaction fram
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment reinforces the Company's financial position and propels its late-stage non-opioid therapeutic programs toward key clinical and regulatory milestones. The financing also facilitates the integration of MindWave Innovations Inc., aligning corporate operations and financial management processes. As part of that integration, approximately 1,000 Bitcoin previously held by MindWave have been transferred into a segregated, risk-managed structure. This digital-asset position is governed under a defined inv
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds' late-stage, non-opioid pain-management biologic portfolio with MindWave's AI-driven Bitcoin treasury, digital asset yield generation, and $NILA-powered ecosystem. The combined company integrates high-growth biotechnology and institutional digital-treasury capabilities, with the merger supported by a simultaneous PIPE of up to $100 million to advance Apimeds' clinical programs and expand MindWave's digital asset infrastructure. (NYSE:APUS) Apimeds Pharmaceuticals US, Inc. ("Apimeds"), a clinical-stage biotechnology company that completed its IPO in May 2025, today announced that i
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College of Business and Economics, beginning in the Spring 2026 semester. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds' commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem. The ai² Futures Lab™ functions as both a discovery engine for potential therapeutic assets and a training ground for the next generation of biotech and business leaders. Through this collaboration, University of Idaho students will work
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the expansion of the Apimeds ai² Futures Lab program through a new collaboration with the University of Oregon's Lundquist College of Business, starting with the Winter 2026 quarter. The initiative connects student teams with real-world biopharma business development projects, reinforcing Apimeds' commitment to fostering innovation, leadership, and discovery across the healthcare ecosystem. ai² Futures Lab functions as both a discovery engine for potential therapeutic assets and a training ground for tomorrow's industry leaders. Through this collaboration, University of Oregon students will engage directly with Apime
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego's Knauss School of Business. The initiative is designed to identify promising pharmaceutical assets critical to improving human health while cultivating the next generation of business leaders for the biopharmaceutical industry. Future Labs is part of Apimeds' ai² innovation platform, connecting university students with real-world strategy and business development projects. Through this collaboration, student teams will work closely with Apimeds mentors to identify and evaluate opportunities to advance developm
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) today welcomed the U.S. Food and Drug Administration's (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting its potential to accelerate the company's lead program, Apitox, for chronic osteoarthritis pain. The draft guidance, entitled "Development of Non-Opioid Analgesics for Chronic Pain, Draft Guidance for Industry", can be found here: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/development-non-opioid-analgesics-chronic-pain. Erik Emerson, Chief Executive Officer of Apimeds, issued the following statement: "The FDA's draft guidance represents a landmark moment for comp
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds") today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse College of Business's STEM Path to the MBA program. The initiative aims to identify important assets critical to improving human health and to cultivate the next generation of pharmaceutical industry business leaders. Future Labs is part of Apimeds' ai² innovation platform, connecting university students with real-world biopharmaceutical strategy and business development projects. Through this partnership, student teams will work closely with Apimeds mentors to identify and evaluate opportunities to advance development
Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical-stage biopharmaceutical company developing Apitox, an intradermally administered, bee venom-based therapeutic, today announced two key additions to its executive leadership team. Susan Kramer, DrPH, has been appointed Senior Vice President of Development, and Brian Peters has joined as Head of the Company's proprietary ai²™ division. Dr. Kramer brings more than 30 years of experience in biopharmaceutical research and development, including 18 years at Genentech. She most recently served as Executive Vice President of Development at Concentric Analgesics. Mr. Peters, previously Chief Strategy & Insights O